Adgero Biopharmaceuticals

About:

Adgero Biopharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline

Website: http://www.adgerobiopharm.com/

Top Investors: SternAegis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Description:

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

Total Funding Amount:

$15.1M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Princeton, New Jersey, United States

Founded Date:

2012-01-01

Contact Email:

jtc(AT)jenenethomascommunications.com

Founders:

Frank Pilkiewicz

Number of Employees:

1-10

Last Funding Date:

2017-09-27

IPO Status:

Private

Industries: